Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 | Q12908 | 17/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PRNP | P04156 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7091229 | 0.98 | SLC10A2 (0.50) | SLC10A2ALDH1A1PRNPGAAMAPT | |
| SCHEMBL5222000 | 0.97 | SLC10A2 (0.46) | SLC10A2ALDH1A1PRNPGAAMAPT | |
| SCHEMBL7091381 | 0.96 | SLC10A2 (0.44) | SLC10A2ALDH1A1PRNPGAAMAPT | |
| SCHEMBL5221960 | 0.92 | SLC10A2 (0.55) | SLC10A2NR1H4 | |
| SCHEMBL3806800 | 0.90 | SLC10A2 (0.38) | SLC10A2ALDH1A1PRNPGAAMAPT | |
| SCHEMBL14559698 | 0.90 | SLC10A2 (0.38) | SLC10A2ALDH1A1PRNPGAAMAPT | |
| SCHEMBL3807196 | 0.89 | NR1H4 (0.47) | SLC10A2NR1H4 | |
| SCHEMBL8015441 | 0.89 | SLC10A2 (0.48) | SLC10A2 | |
| SCHEMBL5222698 | 0.88 | SLC10A2 (0.54) | SLC10A2NR1H4 | |
| SCHEMBL6633251 | 0.88 | SLC10A2 (0.41) | SLC10A2ALDH1A1PRNPGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1345918-B1 | 1,5 BENZOTHIAZEPINES AND THEIR USE AS ANTIHYPERLIPIDEMICS | ASTRAZENECA AB (SE) | 2007-04-18 | — | — | EP | disclosed |
| US-7192945-B2 | Benzothiazepine derivatives | ASTRAZENECA AB (SE) | 2007-03-20 | — | — | US | disclosed |
| US-6906058-B2 | 1,5-Benzothiazepines and their use as hypolipidaemics | ASTRAZENECA AB (SE) | 2005-06-14 | — | — | US | disclosed |
| EP-1263747-B1 | 1,5-BENZOTHIAZEPINES AND THEIR USE AS HYPOLIPIDAEMICS | ASTRAZENECA AB (SE) | 2004-11-24 | — | — | EP | disclosed |
| US-20040067933-A1 | Chemical compounds | ELOBIX AB (SE) | 2004-04-08 | — | — | US | disclosed |
| US-20030166927-A1 | 1,5-Benzothiazepines and their use as hypolipidaemics | ALBIREO AB (SE) | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067933-A1 | Chemical compounds | SLC10A2, SLC10A1, ABCB11 | SLC10A2 1/4885ALDH1A1 546/4885PRNP 4836/4885 |
| US-20030166927-A1 | 1,5-Benzothiazepines and their use as hypolipidaemics | SLC10A2, SLC10A1, LCAT | SLC10A2 1/4885ALDH1A1 811/4885PRNP 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.